title: Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Wilson
authors.initials: W
authors.lastname: Nadruz
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Brian L
authors.initials: BL
authors.lastname: Claggett
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: John J
authors.initials: JJ
authors.lastname: McMurray
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Milton
authors.initials: M
authors.lastname: Packer
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Michael R
authors.initials: MR
authors.lastname: Zile
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Jean L
authors.initials: JL
authors.lastname: Rouleau
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Akshay S
authors.initials: AS
authors.lastname: Desai
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Karl
authors.initials: K
authors.lastname: Swedberg
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Martin
authors.initials: M
authors.lastname: Lefkowitz
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Victor C
authors.initials: VC
authors.lastname: Shi
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
authors.forename: Margaret F
authors.initials: MF
authors.lastname: Prescott
authors.affiliation: From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.). ssolomon@rics.bwh.harvard.edu.
authors.forename: Scott D
authors.initials: SD
authors.lastname: Solomon
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D015260:Neprilysin / Q000037:antagonists & inhibitors / Q000378:metabolism; D009765:Obesity / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology*; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D010446:Peptide Fragments; D011480:Protease Inhibitors; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D015260:Neprilysin
keywords: BNP; NT-proBNP; heart failure; natriuretic peptides; obesity; prognosis